Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis
- DOI
- 10.1007/s11523-025-01185-x
- Published
- 2025-11
- Container
- Targeted Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s11523-025-01185-x,
title = {Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis},
author = {Mallika Lala and Aditya Bardia and Antonio Calles and Romano Danesi and Tomoko Freshwater and Jane A. Healy and Roy S. Herbst},
year = {2025},
journal = {Targeted Oncology},
doi = {10.1007/s11523-025-01185-x},
url = {https://doi.org/10.1007/s11523-025-01185-x}
}RIS
TY - JOUR TI - Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis AU - Mallika Lala AU - Aditya Bardia AU - Antonio Calles AU - Romano Danesi AU - Tomoko Freshwater AU - Jane A. Healy AU - Roy S. Herbst PY - 2025 JO - Targeted Oncology DO - 10.1007/s11523-025-01185-x UR - https://doi.org/10.1007/s11523-025-01185-x ER -
APA
Lala, M., Bardia, A., Calles, A., Danesi, R., Freshwater, T., Healy, J. A., & Herbst, R. S. (2025). Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis. Targeted Oncology. https://doi.org/10.1007/s11523-025-01185-x
Source records
- crossref · retrieved 2026-09-26T06:06:18.729Z